Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Oncologist

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1634/theoncologist.2011-0212PMID 22234627PMCID PMC3267818
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer

  2010cited by this paper
• HER 3 and downstream pathways are involved in colonization of brain metastases from breast cancer

  2010cited by this paper
• Pazopanib Reveals a Role for Tumor Cell B-Raf in the Prevention of HER2+ Breast Cancer Brain Metastasis

  2010cited by this paper
• Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer

  2010cited by this paper
• Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

  2010cited by this paper
• Receptor conversion in distant breast cancer metastases

  2010cited by this paper
• Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark®) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens

  2010cited by this paper
• Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization‐positive patients with metastatic breast cancer treated with trastuzumab

  2010cited by this paper
• Her-2/neu status in breast cancer metastases to the central nervous system.

  2009cited by this paper
• Metastasis: from dissemination to organ-specific colonization

  2009cited by this paper
• Genes that mediate breast cancer metastasis to the brain

  2009influential reference
• A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue

  2009cited by this paper
• Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.

  2009cited by this paper
• Risk factors for brain relapse in HER2-positive metastatic breast cancer patients

  2009cited by this paper
• A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

  2008cited by this paper
• Extended Survival in Women With Brain Metastases From HER2 Overexpressing Breast Cancer

  2008cited by this paper
• Gene expression analysis for prediction of early brain metastasis (BM) in HER2-positive (HER2+) breast cancer patients (pts)

  2008cited by this paper
• Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

  2008cited by this paper
• Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.

  2008cited by this paper
• Subtypes of breast cancer show preferential site of relapse.

  2008cited by this paper
• Defining prognosis for women with breast cancer and CNS metastases by HER2 status.

  2008cited by this paper
• Breast cancer subtypes and survival in patients with brain metastases

  2008cited by this paper
• Survival in patients with brain metastases from breast cancer

  2008cited by this paper
• Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier

  2007cited by this paper
• Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.

  2007cited by this paper
• Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.

  2007cited by this paper
• Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

  2007cited by this paper
• Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.

  2007cited by this paper
• Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.

  2007cited by this paper
• Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR

  2006cited by this paper
• Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.

  2006cited by this paper
• Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.

  2006cited by this paper
• Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.

  2006cited by this paper
• Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.

  2005cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Central nervous system metastases in patients with high‐risk breast carcinoma after multimodality treatment

  2004cited by this paper
• The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma

  2004cited by this paper
• Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer

  2004cited by this paper
• Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): Results from Cancer and Leukemia Group B study 8461 and review of the literature

  2004cited by this paper
• Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment.

  2004cited by this paper
• Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

  2003cited by this paper
• Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival.

  2003cited by this paper
• Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Trastuzumab in CSF.

  2000cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• The distribution of secondary growths in cancer of the breast. 1889.

  1989cited by this paper
• Central nervous system metastasis from breast carcinoma autopsy study

  1983cited by this paper

• Brain recurrence patterns in breast cancer patients with or without postoperative radiotherapy

  2025cites this paper
• T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: preclinical evaluation and mechanisms, prediction, and exploration of adverse effects

  2025cites this paper
• Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients.

  2023cites this paper
• Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease

  2022cites this paper
• Intramedullary spinal cord metastasis to the cauda equina in a patient with HER2-positive metastatic breast cancer: A case report

  2022cites this paper
• Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis

  2021cites this paper
• Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review

  2021influential citation
• Risk factors for breast cancer brain metastases: a systematic review

  2020cites this paper
• Brain metastatic breast cancer: Epidemiology, survival and prognosis: Single center experience

  2020cites this paper
• Stereotactic radiation therapy for breast cancer in the elderly

  2020cites this paper
• Towards a mission‐oriented approach to cancer in Europe: an unmet need in cancer research policy

  2019cites this paper
• A Novel Immunohistochemical Signature with the Quantification of HER2 Predicts the Complete Response in HER2-Positive Breast Cancer

  2019cites this paper
• Genetic Testing for Breast Cancer Gene Expression Prognosis Assay

  2018cites this paper
• Neurological Complications of Breast Cancer and Its Treatment

  2018cites this paper
• External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis.

  2017cites this paper
• Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: a Multicenter Japanese Retrospective Study

  2017cites this paper
• A mission‐oriented approach to cancer in Europe: a joint mission/vision 2030

  2017cites this paper
• Brain Metastasis Prediction by Transcriptomic Profiling in Triple‐Negative Breast Cancer

  2017cites this paper
• Brain Metastases from Breast Cancer in Patients Receiving Trastuzumab

  2016cites this paper
• Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases

  2016cites this paper
• Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions.

  2016cites this paper
• FN 14 and GRP 94 expression are prognostic / predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies

  2016cites this paper
• Applied Proteomics in Breast Cancer

  2016cites this paper
• Chapter 21 – Brain Metastases from Breast Cancer: Focus on Risk Factors, Treatment, and Clinical Outcome

  2016cites this paper
• Quantitative analysis of HER family proteins using mass spectrometry as a predictive tool of response to anti-HER therapies in breast cancer

  2016cites this paper
• [Systemic treatment of brain metastases from breast cancer].

  2015cites this paper
• Quantification of HER family receptors in breast cancer

  2015cites this paper
• Molecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case Presentation

  2015cites this paper
• FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies

  2015cites this paper
• Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis

  2014cites this paper
• Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.

  2014cites this paper
• Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers

  2014cites this paper
• The Role of Type I Insulin-Like Growth Factor Receptor Signaling in Breast Cancer Brain Metastasis

  2013cites this paper
• HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series

  2013cites this paper
• Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51.

  2013cites this paper
• Predictive factors of brain metastasis in patients with breast cancer

  2013cites this paper
• Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis

  2013cites this paper
• Recent advances in drug design of epidermal growth factor receptor inhibitors.

  2013cites this paper
• Chromosomal Analysis: Clinical Applicability to Brain Cancers

  2013cites this paper
• Suppression of HER-2 via siRNA interference promotes apoptosis and decreases metastatic potential of SKOV‑3 human ovarian carcinoma cells.

  2013cites this paper
• Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline

  2013cites this paper
• A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.

  2013cites this paper
• Optimal Management of Brain Metastases from Breast Cancer

  2013cites this paper
• Targeted therapy for brain metastases.

  2012cites this paper
• Brain metastasis: opportunity for drug development?

  2012cites this paper
• C URRENT OPINION Brain metastasis: opportunity for drug development?

  2012cites this paper